Xanomeline
Xanomeline is a selective muscarinic M1/M4 receptor agonist that activates central muscarinic receptors in the prefrontal cortex and striatum, enhancing cholinergic neurotransmission in circuits relevant to cognition, psychosis, and mood regulation. It is under investigation for Alzheimer's disease (cognitive improvement) and schizophrenia (antipsychotic effects without dopamine blockade), and was combined with the peripheral muscarinic antagonist trospium to reduce systemic side effects in the KarXT formulation approved for schizophrenia. Its mechanism represents a novel approach to treating psychosis through central muscarinic agonism rather than dopamine antagonism.
Moleküler Ağırlık
281,4200 g/mol
LogP
3,30
TPSA
66,50 Ų
Lipinski RO5
Geçer
Terapötik Alanlar
Etki Mekanizması
Binds to and activates its target receptor, mimicking the action of the endogenous ligand to produce a specific physiological response.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Binds to and activates its target receptor, mimicking the action of the endogenous ligand to produce a specific physiological response.
2D Yapı
Cite this structure
Embed this structure
SMILES
CCCCCCOc1nsnc1C1=CCCN(C)C1
InChI
InChI=1S/C14H23N3OS/c1-3-4-5-6-10-18-14-13(15-19-16-14)12-8-7-9-17(2)11-12/h8H,3-7,9-11H2,1-2H3
Molecular Formula
C14H23N3OS
HBD / HBA
- / 5
Döndürülebilir Bağlar
7
Ağır Atomlar
19
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Sıkça Sorulan Sorular
Xanomeline is a selective muscarinic M1/M4 receptor agonist that activates central muscarinic receptors in the prefrontal cortex and striatum, enhancing cholinergic neurotransmission in circuits relevant to cognition, psychosis, and mood regulation. It is under investigation for Alzheimer's disease (cognitive improvement) and schizophrenia (antipsychotic effects without dopamine blockade), and was combined with the peripheral muscarinic antagonist trospium to reduce systemic side effects in the KarXT formulation approved for schizophrenia. Its mechanism represents a novel approach to treating psychosis through central muscarinic …
Binds to and activates its target receptor, mimicking the action of the endogenous ligand to produce a specific physiological response.
Yes, Xanomeline is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL21536. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 60809. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="xanomeline"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/xanomeline/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/xanomeline/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/xanomeline/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="xanomeline"></drugfyi-drug>